E3 PreliminaryPreliminaryPEM not requiredReview-NarrativePeer-reviewedReviewed
Standard · 3 min
[Regulatory T-cells: modern approaches to optimization of their numbers].
Pukhal'skiĭ, A L, Shmarina, G V, Aleshkin, V A · Vestnik Rossiiskoi akademii meditsinskikh nauk · 2011
Quick Summary
Your body has special immune cells called regulatory T-cells (Tregs) that normally help control inflammation and keep your immune system balanced. This article explains how long-term stress and aging can disrupt this balance—either causing too many Tregs to build up or too few to develop properly. The authors suggest that when Tregs become imbalanced, it may contribute to conditions like chronic fatigue syndrome, while also affecting allergy and cancer risk.
Why It Matters
ME/CFS is characterized by abnormal immune activation and dysregulated cortisol response—both key factors in the Treg imbalance model proposed here. Understanding whether ME/CFS patients have excess Treg-mediated immunosuppression versus insufficient Treg development could guide future therapeutic approaches to restore immune tolerance and reduce symptom severity.
Observed Findings
Chronic stress and HPA axis activation can lead to accumulation of regulatory T-cells over time
Aging and repeated stress episodes alter the balance between the three principal anti-inflammatory mechanisms (macrophages, Tregs, stress hormones)
Decreased baseline cortisol and reduced stress-induced cortisol response impair the ability to control inflammation in older individuals
Both excess and deficiency of Tregs are associated with morbid conditions—excess with functional somatic syndromes and potential tumor growth, deficiency with allergy and asthma
Inferred Conclusions
Treg dysregulation—either accumulation or insufficiency—underlies the pathogenesis of functional somatic syndromes including chronic fatigue syndrome
The balance between HPA-axis–mediated and Treg-mediated immune tolerance is dynamic and can be disrupted by chronic stress, aging, and antigen load
Restoring appropriate Treg levels through pharmacological intervention may offer a therapeutic strategy for managing ME/CFS and related conditions
Remaining Questions
What is the specific Treg count and subset distribution in ME/CFS patients compared to healthy controls?
Does Treg accumulation precede symptom onset in ME/CFS, or does it develop secondary to chronic immune activation?
What This Study Does Not Prove
This is a theoretical review, not an original empirical study, so it does not present new experimental or clinical data from ME/CFS patients. The proposed link between Treg dysregulation and ME/CFS is conceptual; the review does not prove causation or quantify Treg abnormalities in ME/CFS populations. The mechanisms described are inferred from general immunology principles and may not directly translate to the specific pathophysiology of ME/CFS.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.